12,372 trials
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169 — 0.186; 0.208; 0.223; 0.149 Liters — p=0.377
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 12 — 0.17; -0.62 Percent
Type 2 Diabetes
Primary: First Phase of Insulin Secretion — 13.8; 15.9 µU/ml
Thalassemia · Hypertension, Pulmonary
Primary: Change in Six-minute Walk Test (6MWT) Distance From Baseline to Week 12 Among Sildenafil Group — -1.38 meters — p=0.97
Renal Failure
Primary: Contrast-induced Nephropathy — 6.1; 6.0 percentage of contrast nephropaty
HIV Infections
Primary: Mean Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at Day 8 — -1.06; 0.10 Log 10 copies per milliliter (c/mL)…
Cerebrovascular Disorders · Hemiplegia
Primary: Fugl-Meyer Score Change Immediately Following Study Intervention. — 6.8; 14.4; 14.0 units on a scale
Colitis, Ulcerative
Primary: Number of Participants With Clinical Response at Week 6 — 76; 129; 141 Participants — p=<0.0001
Chronic Kidney Disease Requiring Chronic Dialysis
Primary: Change From Baseline and Levels at Each Time Point for Serum Phosphorus — -0.2; -0.1; -0.2; 0.1 mg/dL
Chronic Hepatitis C
Primary: Percentage of Participants Achieving SVR12 — 78; 0 percentage of participants — p=< 0.001
Hepatitis B
Primary: Percentage of Participants Receiving Subcutaneous Vaccination Who Achieved Seroprotection — 90.1; 82.5 Percentage of participants
Intraocular Retinoblastoma
Primary: Event-free Survival — 0.65 Proportion of participants
Chronic Hepatitis B
Primary: Percentage of Participants With a Virologic Response at Week 48 - Treated Population — 76.1 percentage of participants
Asthma
Primary: Participants With Unscheduled Asthma-related Visits — 29; 26 participants
Critical Illness
Primary: Hospital Mortality Rate — 11; 13 participants